top of page

Imophoron Announces Publication of Scientific Paper Highlighting the Ability of ADDomer to Combat Viral Infections



BRISTOL, UK – 29 November 2023 – Imophoron, a biopharmaceutical company developing thermostable nanoparticle vaccines using its ADDomer™ platform, today announced the publication in Antibody Therapeutics of a scientific research paper demonstrating the potential for the broad application of ADDomer in generating intrinsically thermostable vaccines and reagents to combat viral infections.


The paper, titled "In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2”, explores the cutting-edge technology behind the development of an ADDomer vaccine targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This programme, carried out in collaboration with the University of Bristol, involved an integrated approach combining synthetic, computational and structural methods with in vitro antibody selection and in vivo immunisation to design, produce and validate nature-inspired nanoparticle-based vaccines and reagents. The paper highlights the use of Imophoron’s patented multivalent nanoparticle superbinder technology against SARS-CoV-2, including immune-evasive variants of concern.


Richard Bungay, Chief Executive of Imophoron, commented: “This important paper highlights Imophoron’s unique ADDomer and Gigabody technology platforms and their significant potential in developing novel, thermostable vaccines to combat infectious diseases. It represents a significant milestone for our team of world-class scientists, in collaboration with the excellent team at the University of Bristol, in our ongoing commitment to advancing global health.”


The paper can be downloaded at


For further information, please visit or contact:

Richard Bungay, Chief Executive Officer


About Imophoron

Imophoron was founded in 2017 and has developed a thermostable nanoparticle platform, ADDomer, a disruptive technology for the development of vaccines. The ADDomer platform is focused initially on the development of vaccines to combat present and future infectious diseases, and also has significant potential to treat diseases with high unmet needs such as oncology. The ADDomer platform is based on a self-assembling thermotolerant protein that permits rapid insertion of large numbers of epitopes in a single particle. Imophoron is building a pipeline of thermostable, nanoparticle ADDomer vaccines, including multivalent approaches, to address critical medical challenges that impact communities worldwide.


Imophoron has also developed a novel nanobody platform, Gigabody, which has broad range of potential applications across multiple therapeutic areas.

bottom of page